S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

AVIR Atea Pharmaceuticals Inc

3.09

-0.05 (-1.59%)

22 Feb 2025 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Atea Pharmaceuticals Charts.

Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Atea Pharmaceuticals Charts.

Atea Pharmaceuticals Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 13 January 2025 (1 month ago) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Wednesday 8 January 2025 (1 month ago) • GlobeNewswire Inc.

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Monday 16 December 2024 (2 months ago) • GlobeNewswire Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Wednesday 4 December 2024 (3 months ago) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Tuesday 26 November 2024 (3 months ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Wednesday 20 November 2024 (3 months ago) • Edgar (US Regulatory)

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Saturday 16 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 8 November 2024 (4 months ago) • Edgar (US Regulatory)

More Atea Pharmaceuticals Inc News Articles

National Australia Bank

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions